Physicians May Not Be Removing Enough Breast Tissue in Younger Patients

Publication
Article
OncologyONCOLOGY Vol 14 No 4
Volume 14
Issue 4

Younger women who undergo lumpectomy to remove noninvasive breast cancer cells are significantly more likely to experience a recurrence than older patients, in part, because physicians may not be removing enough breast tissue during

Younger women who undergo lumpectomy to remove noninvasive breast cancer cells are significantly more likely to experience a recurrence than older patients, in part, because physicians may not be removing enough breast tissue during surgery, according to a study conducted by researchers at William Beaumont Hospital in Michigan.

Over a 13-year period, lead author Frank Vicini, md, and his research team followed 146 patients who were treated at the Michigan hospital with breast-conserving therapy (lumpectomy plus radiation) for ductal carcinoma in situ (DCIS). They found that younger patients (ie, those under 45 years old) had a significantly greater rate of cancer recurrence (26.1%) than older women (8.6%). This higher rate of recurrence among younger women was due to surgery that may not have “cleared the margins.”

Extent of Surgery, Not Age, Increases Recurrence

When the researchers looked more closely at the 95 patients who had a second lumpectomy due to concerns that some cancerous tissue remained, they found that the 31 younger patients in this group more frequently had less tissue initially removed than the older patients. Thus, the factor most associated with a poor outcome was not age but the extent of the surgery. “Bigger surgeries offered better results,” said Vicini. He speculated that concern for appearance may have been a primary reason for the removal of too little tissue.

However, Vicini stressed that DCIS can present differently in younger patients. “In younger women, cancer can be spread over a slightly larger area in the breast because the tissue is more dense and has more ducts. As women age, ducts are replaced by fat,” he says. “The surgery needs to meticulously clear the margins in both younger and older women.”

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content